SYNTHESIS OF NINE SAFROLE DERIVATIVES AND THEIR ANTIPROLIFERATIVE ACTIVITY TOWARDS HUMAN CANCER CELLS.

LUIS ESPINOZA CATALÁN^{1*}, ALEJANDRO MADRID VILLEGAS¹, LAUTARO TABORGA LIBER¹, JOAN VILLENA GARCÍA², MAURICIO CUELLAR FRITIS², AND HÉCTOR CARRASCO ALTAMIRANO³.

¹Departamento de Química, Universidad Técnica Federico Santa María, Av. España N° 1680, Valparaíso, Chile.

²Facultad de Farmacia, Universidad de Valparaíso, Av. Gran Bretaña N° 1093, Valparaíso, Chile. Centro Regional de Estudios en Alimentos Saludables (CREAS). Centro de Investigaciones y Desarrollo en Alimentos Funcionales (CIDAF).

³Departamento de Ciencias Químicas, Universidad Andrés Bello, Campus Viña del Mar, Los Fresnos N° 52, Viña del Mar, Chile.

(Received: August 17, 2009 - Accepted: March 25, 2010)

ABSTRACT

Safrole from sassafras oil (*Ocotea pretiosa* Mez., *Lauraceae*), is an abundant natural product showing interesting functionality and chemical structure. Starting from safrole, nine derivatives were prepared and assessed for antiproliferative effect using different human cell lines. The *in vitro* growth inhibition assay was based on the sulphorhodamine dye to quantify cell viability. Some safrole derivatives, (2*E*)-3-(3',4'-methylenedioxy)phenyl acrylaldehyde (**3**) and 4-allyl-5-nitrobenzene-1,2-diol (**4**) presented better antiproliferative effect than the parent compound on two breast cancer cell lines (MCF-7 and MDA-MB-231) and one human colorectal cancer cell line (DLD-1) with IC₅₀ values of 55.0 ± 7.11 µM, 37.5 ± 2.65 µM and 44.0 ± 6.92 µM, respectively, without toxicity towards dermal human fibroblast (DHF cells).

Keywords: Antiproliferative activity, safrole derivatives, synthesis.

INTRODUCTION

Cancer is the largest single cause of death in men and women. Recently, resistance to anticancer drugs has been observed. Therefore, the research and development of more effective and less toxic drugs by the pharmaceutical industry has become necessary. Many substances derived from dietary or medicinal plants are known to be effective and versatile chemopreventive and antitumoral agents in a number of experimental models of carcinogenesis. Safrole, from sassafras oil (*Ocotea pretiosa* Mez., *Lauraceae*), is an abundant natural product showing interesting functionality and chemical structure. The methylenedioxy unit, present in safrole, can be identified in the clinical antitumour agents etoposide and teniposide¹ and lignan lactone podophylotoxin².

We have shown what eugenol and this derivatives present antioxidant capacity evaluated by the DPPH (1,1-diphenyl-2-picrylhydrazil) and ORAC assays. Eugenol derivatives exhibited a haemolysis percentage lower than 1%, which indicate very low toxicity for red blood cell membranes.³ *In vitro* studies carried out on two human cancer cell lines: DU-145 (androgen-insensitive prostate cancer cells) and KB (oral squamous carcinoma cells) measuring cell viability by the tetrazolium salt assay. Lactic dehydrogenase (LDH) release was also measured to evaluate cell toxicity as a result of cell disruption, subsequent to membrane rupture. In the examined cancer cells, all compounds showed cell-growth inhibition. The results indicate that the compounds 5-allyl-3-nitrobenzene-1,2-diol and 4-allyl-2-methoxy-5-nitrophenyl acetate were significantly more active than eugenol ($p < 0.001$), with IC₅₀ values of 19.02 × 10⁻⁶ and 21.5 × 10⁻⁶ mol L⁻¹, respectively, in DU-145 cells and 18.11 × 10⁻⁶ and 21.26 × 10⁻⁶ mol L⁻¹, respectively, in KB cells, suggesting that the presence of nitro and hydroxyl groups could be important in the activity of these compounds. In addition, our results suggest that apoptosis is induced in KB and DU-145 cells. In fact, in our experimental conditions, no statistically significant increase in LDH release was observed in cancer cells treated with eugenol and its analogues.⁴ This results suggest that structural analogous of eugenol bearing a nitro group and a hydroxyl group can present antiproliferative/cytotoxic effect on cells.

Antiproliferative screening *in vitro* provide preliminary data to select compounds with potential antineoplastic properties. Safrole (**1**) and its synthetic derivatives (**2-8**) were tested *in vitro* for antiproliferative effect on two human tumor breast cancer cell lines (MDA-MB-231, MCF-7), one human colorectal cancer cell line (DLD-1) and one dermal human fibroblast cell line (DHF). The *in vitro* growth inhibition assay used was based on sulphorhodamine dye, widely used to quantify cell viability.

EXPERIMENTAL

General

Safrole was obtained commercially from Sigma-Aldrich, and other chemical reagents were purchased (Merck or Aldrich) with the highest purity commercially available and were used without previous purification. IR spectra were obtained by using KBr pellets or thin films in a Nicolet Impact 420 spectrometer. Frequencies are reported in cm⁻¹. Low resolution mass spectra were recorded on a Shimadzu QP-2000 spectrometer at 70eV ionising voltage and are given as m/z (% rel. int.) ¹H, ¹³C (DEPT 135 and DEPT 90). Some spectra were recorded in CDCl₃ solutions and were referenced to the residual peaks of CHCl₃, δ=7.26 ppm and δ=77.0 ppm for ¹H and ¹³C, respectively; CD₂COCD₃ solutions were referenced to the residual peaks of CH₃COCH₃, δ=2.04 ppm and δ=29.8 ppm for ¹H and ¹³C, respectively, on a Bruker Avance 400 Digital NMR spectrometer operating at 400.1MHz for ¹H and 100.6 MHz for ¹³C. Chemical shifts are reported in δ ppm and coupling constants (J) are given in Hz. Silica gel (Merck 200-300 mesh) was used for C.C. and silica gel plates HF-254 for TLC. TLC spots were detected by heating after spraying with 25% H₂SO₄ in H₂O.

Synthesis

4-allyl-5-nitro-1,2-methylenedioxybenzene (**2**) and (2*E*)-3-(3',4'-methylenedioxy)phenyl acrylaldehyde (**3**)

To a solution of safrole **1** in acetic acid (8 mL) at -5 °C (2.0 g, 12.3 mmol) a solution of nitric acid and sulphuric acid at -5 °C (10:1 ratio; 2.5 mL) was added dropwise. The mixture at -10 °C was stirred for 4 h, taken up in water (10mL) and extracted with ethyl acetate (EtOAc, 3 x 50 mL). The organic layer was washed to neutrality with a saturated NaHCO₃ solution, dried over MgSO₄ and taken to dryness under reduced pressure. The residue was chromatographed on a silica gel column with mixtures of petroleum ether (PE)/EtOAc of increasing polarity (19.8:0.2→17.8:2.2). After TLC comparison, 1.86 g (75.0%) of compound **2** and 0.11 g (5.2%) of compound **3** were obtained. **Compound 2**, red viscous oil; **IR** (cm⁻¹): 3081 (=C-H); 2912 (C-H); 1616 (C=C); 1523 (-NO₂); 1480 (C=C); 1421 (-CH₂); 1328 (N=O); 1257 (C-O-C); 927 (-C-O-C-); 817 (-C-H). **M.S.** (m/z, %): 208 (2.8); 207 (23.0); 190 (100); 177 (21.0); 176 (17.5); 173 (50.2); 162 (16.9); 160 (23.0); 132 (29.7); 103 (24.9); 102 (51.3); 77 (43.9); 76 (22.6); 53 (16.2); 51 (19.4). **¹H NMR**: 7.49 (s, 1H, H-6); 6.76 (s, 1H, H-3); 6.09 (s, 2H, OCH₂O); 5.95 (ddt, 1H, 1H, J=17.0, 10.3 and 6.5 Hz, H-2'); 5.10 (m, 2H, H-3'); 3.65 (d, 2H, J=4.0 Hz, H-1'); **¹³C NMR**: 151.7 (s, C-2); 146.5 (s, C-5 and s, C-1); 135.2 (d, C-2'); 132.2 (s, C-4); 117.0 (t, C-3'); 110.4 (d, C-3); 105.7 (t, OCH₂O); 102.7 (d, C-6); 37.6 (t, C-1'); **Compound 3**, yellow viscous oil; **IR** (cm⁻¹): 2913 (C-H); 2825 (C-H);

1724 (C=O); 1663 (C=C-C=O); 1610 (C=C); 1492 (C=C); 1254 (C-O-C); 938 (C-O-C). **¹H NMR:** 9.65 (d, 1H, J=7.7 Hz, H-3'); 7.38 (d, 1H, J=15.8 Hz, H-1'); 7.08 (dd, 2H, J=1.7 and J=8.6 Hz, H-5); 7.06 (d, 1H, J=1.7 Hz, H-3); 6.86 (d, 1H, J=8.6 Hz, H-6); 6.56 (dd, 1H, J=7.7 Hz and J=15.8 Hz, H-2'), 6.04 (s, 2H, OCH₂O); **¹³C NMR:** 193.9 (d, CHO); 152.9 (d, C-1'); 150.1 (s, C-1); 148.5 (s, C-2); 128.3 (s, C-4); 127.0 (d, C-2'); 124.7 (d, C-5); 107.7 (d, C-3); 107.3 (d, C-6); 101.0 (t, OCH₂O).

4-allyl-5-nitrobenzene-1,2-diol (4)

To a cold suspension of AlCl₃ (0.68 g, 5.1 mmol) in CH₂Cl₂ (5.0 mL) at 0 °C (under N₂ atmosphere) a solution at -5 °C of **2** (0.30 g, 1.5 mmol) in CH₂Cl₂ (7.0 mL) was slowly added. The resulting mixture was stirred for 2 h at -10 °C. Cold water was added to the mixture (approx. 10 mL). The resulting mixture was stirred for 18 h at room temperature under nitrogen. The reaction mixture was poured into brine solution and extracted with EtOAc (3 x 100 mL). The organic layer was washed with brine then dried over MgSO₄, filtered, evaporated and re-dissolved in 5 mL of acetone. After that, it was adsorbed on silica, chromatographed by CC eluting with mixtures of petroleum ether/EtOAc of increasing polarity (17.0:3.0→15.0:5.0) to give **4**, an orange oil (0.16 g, 57.4%). **IR** (cm⁻¹): 3311 (O-H); 2907 (C-H); 1598 (C=C); 1526 (NO₂); 1495 (C=C); 1429 (-CH₂); 1326 (N=O); 1275 (C-O); 1045 (-C-OH); 809 (-C-H). **¹H NMR:** 8.99 (bs, 2H, OH); 7.57 (s, 1H, H-6); 6.84 (s, 1H, H-3); 5.95 (ddt, 1H, J=17.0, 10.3 and 6.5 Hz, H-2'); 5.03 (m, 2H, H-3'); 3.61 (d, 2H, J=6.4 Hz, H-1'); **¹³C NMR:** 151.3 (s, C-2); 144.4 (s, C-1); 141.4 (d, C-5); 137.1 (d, C-2'); 129.7 (s, C-4); 118.4 (t, C-3'); 116.3 (d, C-3); 113.0 (d, C-6); 37.6 (t, C-1').

3-(3',4'-methylenedioxy)phenyl propan-1-ol (5) and 1-(3',4'-methylenedioxy)phenyl propan-2-ol (6)

The compound **1** (1.0 g, 6.2 mmol) to -5 °C, under N₂ atmosphere was slowly hydroborated with a 2.0 M solution of BH₃·DMS/THF (0.67 mL) at -10 °C for 15 min was added dropwise. Then the mixture was stirred at room temperature for 1 h. The resulting organoborane is oxidized with sodium perborate (0.95 g, 6.2 mmol) and water (100 mL). The mixture was stirred at room temperature for 2 h. Then, it was extracted with portions of ethyl ether (4 x 50 mL) and the layers were separated. The organic layer was dried over MgSO₄, filtered, evaporated and re-dissolved in 5 mL of CH₂Cl₂. It was adsorbed on silica, chromatographed by CC eluting with mixtures of petroleum ether/EtOAc of increasing polarity (18.8:1.2→17.6:2.4). Then two fractions were obtained: fraction I (0.66 g (59.4%) of compound **5**) and fraction II (12 mg (1.1%) of isomer compound **6**). **Compound 5**, yellow viscous oil; **IR** (cm⁻¹): 3330 (O-H); 2909 (C-H); 1495 (C=C); 1439 (-CH₂); 1245 (C-O-C); 1039 (C-OH); 932 (C-O-C); 811 (-C-H). **M.S.** (m/z, %): 181 (6.2); 180 (51.6); 136 (51.2); 135 (100); 119 (5.4); 106 (9.5); 105 (7.8); 104 (5.1); 91 (10.5); 78 (7.1); 77 (19.7); 65 (7.3); 51 (8.6). **¹H NMR:** 6.73 (d, 1H, J=7.6 Hz, H-6); 6.69 (d, 1H, J=1.4 Hz, H-3); 6.64 (dd, 1H, J=1.4 and J=7.6 Hz, H-5); 5.91 (s, 2H, OCH₂O); 3.65 (t, 2H, J=6.4 Hz, H-3'); 2.62 (t, 2H, J=7.4 Hz, H-1'); 1.84 (dt, 2H, J=6.4 and J=15.2 Hz, H-2'); 1.56 (bs, 1H, OH); **¹³C NMR:** 147.5 (s, C-2); 145.6 (s, C-1); 135.6 (s, C-4); 121.1 (d, C-5); 108.8 (d, C-6); 108.1 (d, C-3); 100.7 (t, OCH₂O); 62.1 (t, C-3'); 34.4 (t, C-1'); 31.7 (t, C-2'). **Compound 6**, yellow viscous oil; **IR** (cm⁻¹): 3411 (O-H); 2910 (C-H); 1495 (C=C); 1439 (-CH₂); 1367 (CH₃); 1245 (C-O-C); 1036 (-C-OH); 935 (C-O-C); 803 (-C-H). **¹H NMR:** 6.77 (d, 1H, J=7.8 Hz, H-6); 6.71 (d, 1H, J=1.5 Hz, H-3); 6.65 (dd, 1H, J=1.5 and J=7.8 Hz, H-5); 5.93 (s, 2H, OCH₂O); 3.96 (m, 1H, H-2'); 2.71 (dd, 1H, J=4.7 and J=13.6 Hz, H-1'); 2.59 (dd, 2H, J=8.1 and J=13.6 Hz, H-1'); 1.6 (bs, 1H, OH); 1.23 (d, 3H, J=6.2 Hz, H-3'); **¹³C NMR:** 147.8 (s, C-2); 146.2 (s, C-1); 132.2 (s, C-4); 122.3 (d, C-5); 109.7 (d, C-6); 108.3 (d, C-3); 100.9 (t, OCH₂O); 68.9 (d, C-2'); 45.4 (t, C-1'); 22.7 (c, C-3').

3-(3',4'-methylenedioxy-6'-nitro)phenyl propan-1-ol (7) and 1-(3',4'-methylenedioxy-6'-nitro)phenyl propan-2-ol (8)

Some 0.30 g (1.5 mmol) of compound **2** at -5 °C under N₂ atmosphere was hydroborated with a 2.0 M solution of BH₃·DMS/THF (0.27 mL) at -10 °C for 15 min. The reagent was added dropwise and the mixture was stirred at room temperature for 1 h. The resultant organoborane was oxidized with sodium perborate solution (0.28 g, 1.5 mmol) in water (100 mL). The mixture was stirred at room temperature for 2 h and then extracted with ethyl ether (Et₂O, 4 x 50 mL). The organic layer was dried over MgSO₄, filtered and taken to dryness. The residue was adsorbed on silica gel and chromatographed by CC eluting with mixtures of PE/EtOAc of increasing polarity (16.0:4.0→14.0:6.0). Two fractions were obtained: 0.17 g (53.1%) of compound **7** and 7.8 mg (2.4%) of compound **8**. **Compound 7**, dark yellow solid, mp (85.9-87.9°C); **IR** (cm⁻¹): 3211 (O-H); 2907 (C-H); 1613 (C=C); 1521 (NO₂); 1419 (-CH₂); 1337

(N=O); 1260 (C-O-C); 1045 (-C-OH); 922 (C-O-C); 825 (-C-H). **¹H NMR:** 7.46 (s, 1H, H-6); 6.76 (s, 1H, H-3); 6.08 (s, 2H, OCH₂O); 3.71 (t, 2H, J=6.2 Hz, H-3'); 2.96 (dd, 2H, J=6.4 and J=8.6 Hz, H-1'); 1.90 (m, 2H, H-2') 1.50 (bs, 1H, OH); **¹³C NMR:** 151.7 (s, C-2); 146.3 (s, C-1); 142.8 (s, C-5); 134.4 (s, C-4); 110.6 (d, C-3); 105.7 (d, C-6); 102.7 (t, OCH₂O); 62.0 (t, C-3'); 33.4 (t, C-2'); 30.1 (t, C-1'). **Compound 8**, dark yellow solid, mp (92.6-94.1°C); **IR** (cm⁻¹): 3241 (O-H); 2921 (C-H); 1620 (C=C); 1515 (NO₂); 1481 (-CH₂); 1378 (-CH₃); 1325 (N=O); 1258 (C-O-C); 1031 (-C-OH); 921 (C-O-C); 866 (-C-H). **¹H NMR:** 7.50 (s, 1H, H-6); 6.80 (s, 1H, H-3); 6.09 (d, 2H, J=0.6 Hz, OCH₂O); 4.11 (m, 1H, H-2'); 3.14 (dd, 1H, J=3.9 and J=13.5 Hz, H-1'); 2.88 (dd, 1H, J=8.3 and J=13.5 Hz, H-1'); 1.59 (bs, 1H, OH); 1.31 (d, 3H, J=6.2 Hz, H-3'); **¹³C NMR:** 151.5 (s, C-2); 146.7 (s, C-5 and s, C-1); 131.2 (s, C-4); 111.6 (d, C-3); 105.7 (t, OCH₂O); 102.8 (d, C-6); 68.4 (d, C-2'); 42.9 (t, C-1'), 23.7 (c, C-3').

4-allyl-5-nitro-1,2-phenylene diacetate (9)

To a solution of **4** (0.38 g, 1.92 mmol) in dry CH₂Cl₂ (60 mL), DMAP (3.75 mg) and Ac₂O (0.36 mL, 3.84 mmol) were added and the mixture was stirred at room temperature for 2 h. A cooled solution of 10% KHSO₄ (approx. 50 mL) was then added to this mixture. The watery layer was discarded and the organic layer was washed to neutrality with a saturated solution of NaHCO₃ and water. Then it was dried over MgSO₄, filtered, evaporated and re-dissolved in 5 mL of CH₂Cl₂. Subsequently, it was adsorbed on silica and chromatographed by CC with petroleum ether/EtOAc mixtures of increasing polarity (19.8:0.2→16.4:3.6) to give **9**, (0.50 mg, 94.3%), a dark yellow solid, mp (62.0-63.7°C); **IR** (cm⁻¹): 3083 (=C-H); 2938 (C-H); 1779 (C=O); 1639 (C=C); 1527 (C=C); 1370 (CH₃); 1272 (C-O-C). **M.S.** (m/z, %): 237 (18.4); 220 (25.2); 195 (48.1); 179 (12.9); 178 (100); 165 (40.1); 164 (21.8); 161 (25.0); 149 (11.3); 147 (13.3); 91 (9.5); 65 (10.4). **¹H NMR:** 7.87 (s, 1H, H-6); 7.21 (s, 1H, H-3); 5.92 (ddt, 1H, J=17.1, 10.2 and 6.6 Hz, H-2'); 5.12 (m, 2H, H-3'); 3.67 (d, 2H, J=6.6 Hz, H-1'); 2.30 (s, 6H, CH₃). **¹³C RMN:** 167.4 (s, 2xCH₃CO); 145.7 (s, C-5); 145.5 (s, C-2); 140.3 (s, C-1); 134.2 (t, C-2'); 134.0 (s, C-4); 126.2 (d, C-3); 120.6 (t, C-3'); 117.9 (d, C-6); 36.5 (t, C-1'); 20.4 (c, 2xCH₃CO).

3-(3',4'-methylenedioxy-6-nitro)phenylpropyl acetate (10)

To a solution of **7** (97.8 mg, 0.43 mmol) in dry CH₂Cl₂ (30 mL), DMAP (0.98 mg) and Ac₂O (40.7 µL, 0.43 mmol) were added and the mixture was stirred at room temperature for 2 h. A cooled solution of 10% KHSO₄ (50 mL approx) was then added to this mixture. The watery layer was discarded and the organic layer was washed to neutrality with a saturated solution of NaHCO₃ and water. It was dried over MgSO₄, filtered, evaporated and re-dissolved in 5 mL of CH₂Cl₂ and adsorbed on silica, chromatographed by CC and eluting with petroleum ether/EtOAc mixtures of increasing polarity (19.8:0.2→19.0:1.0) to give **10**, an dark yellow oil (110.4 mg, 95.1%). **IR** (cm⁻¹): 2778 (C-H); 1735 (C=O); 1619 (C=C); 1516 (NO₂); 1425 (-CH₂); 1379 (CH₃); 1330 (N=O); 1260 (C-O-C); 1255 (C-O-C); 928 (C-O-C); 817 (-C-H). **M.S.** (m/z, %): 208 (16.0); 191 (13.6); 190 (100); 189 (14.5); 178 (23.1); 173 (9.2); 163 (19.9); 148 (13.7); 136 (13.3); 135 (13.1); 132 (15.7); 104 (9.9); 77 (12.2). **¹H NMR:** 7.43 (s, 1H, H-6); 6.69 (s, 1H, H-3); 6.05 (s, 2H, OCH₂O); 4.07 (t, 2H, J=6.3 Hz, H-3'); 2.89 (m, 2H, H-1'); 2.03 (s, 3H, CH₃); 1.93 (m, 2H, H-2'). **¹³C NMR:** 170.4 (s, CH₃CO); 151.6 (s, C-2); 146.3 (s, C-1); 142.6 (s, C-5); 133.5 (s, C-4); 110.6 (d, C-3); 105.6 (t, OCH₂O); 102.7 (d, C-6); 63.4 (t, C-3'); 30.5 (t, C-2'); 29.3 (t, C-1'); 20.8 (c, CH₃CO).

Cell Culture

The cell cultures used were obtained from American Type Culture Collection (Rockville, MD, USA). Breast cancer cell lines (MDA-MB-231, MCF-7), a colorectal cancer cell line (DLD-1) and human dermal fibroblast (DHF) were grown in DMEM-F12 medium containing 10% fetal calf serum (FCS), 100 IU/mL penicillin, 100 µg/mL streptomycin and 1 mM L-glutamine. Cells were seeded into 96 well microtiter plates in 100 µL at plating density of 3x10³ cells/well. After 24 h incubation at 37°C (under a humidified 5% carbon dioxide atmosphere to allow cell attachment) the cells were treated with different concentrations of safrrole and derivatives (0-100 µM) and daunorubicin (0.05-50 µM) and incubated for 72 h under the same conditions. Stock solutions of compounds were prepared in ethanol and the final concentration of this solvent was kept constant at 1%. Control cultures received 1% ethanol alone.

Cell viability was determined by the sulforhodamine B assay according to Skehan et al. 1990⁵ with some modifications⁶. Briefly, at the end of drug exposure, cells were fixed with 50% trichloroacetic acid at 4°C (TCA final concentration 10%). After washing with distilled water, cells were stained with 0.1% sulforhodamine B (Sigma-Aldrich, St. Louis, MO), dissolved in

1% acetic acid (50 μ L/well) for 30 min, and subsequently washed with 1% acetic acid to remove unbound stain. Protein-bound stain was solubilized with 100 μ L of 10mM unbuffered Tris base. The cell density was determined using a fluorescence plate reader (wavelength 540nm). Values shown, are the mean $\pm$ SD of three independent experiments in triplicate.

RESULTS AND DISCUSSION

Synthesis Nitrosafrole (**2**) obtained under standard conditions⁷⁻¹⁰ (HNO₃/H₂SO₄/HAc) afforded the nitro compound **2** and aldehyde **3** with 75.0% and 5.2% yields respectively (scheme 1). Oxidative hydroboration of the side chain of nitrosafrole led to an alcohol at C-3'. Nitrosafrole was oxidized using BH₃·DMS/THF/NaBO₃·4H₂O/H₂O as previously described for other alkenes and alkynes¹¹. The primary alcohol **7** was obtained with a 53.1% w/w yield and the secondary alcohol **8** with 2.4% yield (scheme 1).

All the compounds were characterized mainly by NMR, IR and MS spectral data. In the ¹H NMR spectrum of nitrosafrole **2**, two signals at δ =7.49 (s, 1H); 6.76 (s, 1H) were assigned to H-6 and H-3 respectively. In the ¹³C NMR spectrum the signals of C-5 and C-1 were observed at δ =146.5 ppm for a pair of overlapping quaternary carbons which corresponds to a C-5 linked to the nitro group.

In the IR spectrum of compound **3**, the absorption at 1724 cm⁻¹ was assigned to an aldehyde carbonyl group, whereas in the ¹H NMR spectrum the signal at δ =9.65 (d, 1H, J=7.7 Hz) was assigned to an aldehyde associated to the signals at δ =7.38 (d, 1H, J=15.8 Hz) and 6.56 (dd, 1H, J=7.7 Hz and J=15.8 Hz) corresponding to an α , β unsaturated system (H-2' and H-1'). Cleavage of the methylenedioxy ring of nitrosafrole took place during the conversion into the catechol **4** (57.4% yield) using the AlCl₃/CH₂Cl₂/H₂O method¹²⁻¹⁵. In the ¹H NMR spectrum, the absence of the methylenedioxy singlet between 5.90-6.05 ppm confirmed the presence of catechol coupled with a broad signal at δ =8.99 (brs, 2H). The MS spectrum from the diacetate derivative **9** showed two peaks at m/z 220 (25.2%) and 161 (25.0%) attributed to the loss of two acetate groups.

Oxidative hydroboration of the side chain in safrole **1** was carried out to obtain the alcohol at C-3' using the BH₃·DMS/THF/NaBO₃·4H₂O/H₂O method. As in the previous oxidation, the primary alcohol **5** was obtained with a 59.4% and the secondary alcohol **6** with 1.1%w/w yield^{11,16-18} (scheme 1). In the ¹H NMR spectrum of compound **5**, three signals at δ =3.65 (t, 2H, J=6.4 Hz); 2.62 (t, 2H, J=7.4 Hz) and 1.84 (dt, 2H, J=6.4 and J=15.2 Hz) are in agreement with the saturated side chain. In the ¹³C NMR spectrum, the three CH₂ signals at 62.1; 34.4 and 31.7 ppm were to assigned at C-3', C-1' and C-2' respectively and the signal at δ = 62.1 ppm confirms the presence of primary carbinolic carbon. The structure of compound **6** differs mainly from that of **5** in the side chain signals because in the ¹H NMR spectrum signal at δ =3.96 (m, 1H) and 1.23 (d, 3H, J=6.2 Hz) were observed, indicating the presence of secondary alcohol.

In the ¹H NMR spectrum of compound **7**, three signals at δ =3.71 (t, 2H, J=6.2 Hz); 2.96 (dd, 2H, J=6.4 and J=8.6 Hz) and 1.90 (m, 2H) were assigned to the saturated side chain H-3', H-1' and H-2', respectively. On the other hand, the MS spectrum from the acetate **10** presented a molpeak at m/z 163 [M⁺] (19.9) was observed.

In the ¹H NMR spectrum of isomer **8**, the presence of signal at δ = 4.11 ppm (m, 1H) was assigned to carbinolic hydrogen in C-2' position (secondary alcohol). In addition the signal at δ =1.31 (d, 3H, J=6.2 Hz) was assigned an terminal methyl group.

Scheme 1. Conditions: **a.** HNO₃/H₂SO₄ (10:1), HAc (glacial), -10°C, 4h, **2**; 75.0% and **3** 5.2%. **b.** i) BH₃·DMS, THF, (2M); N₂, -10°C, 15min, and r.t, 1h; ii) NaBO₃·4H₂O/ H₂O, r.t, 2h; **5**; 59.4%; **6**; 1.1%; **7**; 53.1% and **8**; 2.4%. **c.** Ac₂O, DMAP, CH₂Cl₂, 2h, r.t; **10**; 95.1%. **d.** i) AlCl₃/CH₂Cl₂; N₂, -10°C, 2h ii) H₂O, r.t, 18h; **4**; 57.4%. **e.** Ac₂O, DMAP, CH₂Cl₂, 2h, r.t.; **9**; 94.3%.

Biological Results

The *in vitro* cytotoxic evaluation of safrole **1** and the compounds **2-8** (see Scheme 1) indicate that the cell viability expressed as % vs. control vehicle (ethanol 1%) for the compounds **3** and **4** was dose-dependant (mM). The IC₅₀ values of compounds **3**, **4**, safrole and the reference compound daunorubicin are summarized in Table 1 as the micromolar concentration that produces 50% cell growth inhibition after 72 hours of drug exposure. The results indicate that derivatives **3** and **4** are more toxic than safrole against MCF-7 cells and that compound **4**, present higher toxicity against all the cancer cells tested than the parent compound and the derivative **3**. The activity of compounds **2**, **5**, **6**, **7** and **8** was comparable to that of safrole (data not shown). However, daunorubicin is at least one hundred times more active as anticancer compound against MDA-MD231 cells and 300-500 times more effective towards MCF-7 cells than the safrole derivatives **3** and **4**. Nevertheless, it is important to emphasize that compound **4** has 10 times less cytotoxicity than daunorubicin against normal cells, an interesting characteristic.

Table 1. Cytotoxic activity of synthesized derivatives safrole compounds against two breast cancer cell lines, MCF-7, MDA-MB231, one colon cancer cell line, DLD-1 and a dermal human fibroblast cells, DHF, expressed as inhibitory concentration IC₅₀.

Compounds	IC ₅₀ (μM)			
	MCF-7	MDA-MB231	DLD-1	DHF
3	80 $\pm$ 6.92	> 100	> 100	> 100
4	55.0 $\pm$ 7.11	37.5 $\pm$ 2.65	44.0 $\pm$ 6.92	> 100
Daunorubicin	0.16 $\pm$ 0.02	0.35 $\pm$ 0.04	0.24 $\pm$ 0.03	12.3 $\pm$ 1.81
Safrole	> 100	> 100	> 100	> 100

Safrole has been shown to become cytotoxic to various human cell types at higher concentrations (5–10 mM)^{19,20}. In the other hand our data showed that the cytotoxic activity of **3** and **4**, is reached at micromolar concentrations, what indicates that these derivatives proved to be more toxic than safrole itself against the selected cancer cells.

CONCLUSION

In synthetic terms, the classic nitration method used for the synthesis of compound **2** led to better yields than those previously reported in literature. An increase in the yields of primary alcohols with lower amounts of the secondary alcohol was achieved preparing the organoborane complex at -10 °C, omitting the use of solvents and an alkaline environment external to the oxidation process

carried out by the sodium per borate in water. The formation of catechols from safrol with AlCl_3 was favoured by the presence in the molecule of the electron attractor group (NO_2). The safrole derivatives **3** and **4** proved to be more toxic than safrole itself against the selected cancer cells.

ACKNOWLEDGEMENTS

The authors thank Universidad de Valparaiso (grant DIPUV 27/2006), Universidad Técnica Federico Santa María (grant DGIP N° 13.08.59, N° 13.09.42 and PIIC 2009) and Universidad Andrés Bello (grant DI-18-08/R) for financial support.

REFERENCES

- 1.- Chen, G. L.; Yang, L.; Rowe, T. C.; Halligan, B. D.; Tewey, K.; Liu, L.; *J. Biol. Chem.*, **259**, 13560, (1984).
- 2.- Capilla, A. S.; Sanchez, I.; Caignard, D. H.; Renard, P.; Pujol, M. D.; *Eur. J. Med. Chem.*, **36**, 389, (2001).
- 3.- Hidalgo, M.E.; Carrasco, H.; Espinoza, L.; De la Rosa, C.; Cardona, W.; Gallardo, C.; *Quím. Nova.*, **32**, 1467, (2009).
- 4.- Carrasco, H.; Espinoza, L.; Cardile, V.; Gallardo, C.; Cardona, W.; Lombardo, L.; Catalán, K.; Cuellar, M. and Russo, A.; *J. Braz. Chem. Soc.*, **19**, 543, (2008).
- 5.- Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR; *J. Nat. Cancer Inst.*, **82**, 1107, (1990).
- 6.- Vichai, V. and K. Kirtikara; *Nature Protocols*, **1**, 1112, (2006).
- 7.- Da Rosa, F., Revelo, R., Nascimento, M.; *J. Braz. Chem. Soc.*, **14**, 11, (2003).
- 8.- Khadem, S., Joseph, R., Rategar, M., Leek, D.M., Outdatchin, K.A., Arya, P.; *J. Comb. Chem.*, **6**, 724, (2004).
- 9.- Leite, A.C, Peixoto, K., De Souza, I., De Araujo, J.M., Brondani, D.J.; *Eu. J. Med. Chem.*, **39**, 1059, (2004).
- 10.- Nascente, L., Ceripes, V., Romeiro, L.; Sociedade Brasileira de Química, 29ª Reunion Anual SBQ, 2005.
- 11.- Kabalka, G.W., Shoup, T.M. and Goudgaon, N.M.; *J. Org. Chem.*, **54**, 5930, (1989).
- 12.- Lange, R. G., *J. Org. Chem.*, **27**, 2037, (1962).
- 13.- Avery, M. A., Verlander, M. S. and Goodman M., *J. Org. Chem.*, **45**, 2750, (1980).
- 14.- De Amorim, M., Da Silva, A. J. M. and Costa, P. R. R.; *J. Braz. Chem. Soc.*, **12**, 346, (2001).
- 15.- Costa, P.R.R.; *Quím. Nova*, **23**, 357, (2000).
- 16.- Backes, M., Von der Fakultät für Mathematik, Informatik und Naturwissenschaften der Rheinisch-Westfälischen Technischen Hochschule Aachen zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften, mai, 2004.
- 17.- Cox, M., Klass, G.; *F. Sci. Inter.*, **164**, 138, (2006).
- 18.- Barreiro, E. J., Fraga, C.A.M.; *Quím. Nova*, **22**, 744, (1999).
- 19.- Hung, S. L.; Chen, Y. L.; *J. Periodontal Res.*, **38**, 130, (2003).
- 20.- M., Uhl, C., Helma, S., Knasmuller; *Mutat. Res.*, **468**, 213, (2000).